Table 3.
Results of the Consensus Conference on the role of betahistine in the therapy of long lasting hearing loss, fullness and tinnitus. 1 = absolutely disagree, 2 = disagree, 3 = agree, 4 = more than agree, and 5 = absolutely agree. Consensus was reached when the sum of items 1 and 2 or 3, 4, and 5 reached 66%. Same asterisk convention.
| 1 | 2 | 3 | 4 | 5 | |
|
| |||||
| In the therapy of hearing loss in the Menière's disease, do you think that betahistine: | |||||
|
| |||||
| 1. Is the first-choice drug in monotherapy | 31% | 29% | 33% | 0% | 7% |
|
| |||||
| 60% ∗∗ | 40% ∗∗ | ||||
|
| |||||
| 2. Is useful when associated to other therapies in the early stages and in the advanced phases of the disease | 18% | 22% | 50% | 4% | 6% |
|
| |||||
| 40% ∗∗ | 60% ∗∗ | ||||
|
| |||||
| 3. Is useful when associated to other therapies ONLY in the early stages of the disease | 11% | 26% | 44% | 14% | 5% |
|
| |||||
| 37% ∗∗ | 63% ∗∗ | ||||
|
| |||||
| 4. Shows poor efficacy | 2% | 17% | 52% | 12% | 17% |
|
| |||||
| 19% | 81% ∗∗∗ | ||||
|
| |||||
| In the therapy of tinnitus in the Menière's disease, do you think that betahistine: | |||||
|
| |||||
| 1. Is the first-choice drug in monotherapy | 13% | 50% | 26% | 7% | 4% |
|
| |||||
| 63% ∗∗ | 37% ∗∗ | ||||
|
| |||||
| 2. Is useful when associated to other therapies | 6% | 23% | 51% | 13% | 7% |
|
| |||||
| 29% | 71% ∗∗∗ | ||||
|
| |||||
| 3. Is not useful | 10% | 53% | 27% | 7% | 3% |
|
| |||||
| 63% ∗∗ | 37% ∗∗ | ||||
|
| |||||
| 4. Shows poor efficacy | 7% | 34% | 46% | 7% | 6% |
|
| |||||
| 41% ∗∗ | 59% ∗∗ | ||||